The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress).
 
Judah D. Friedman
Stock and Other Ownership Interests - Abbott
Honoraria - Amgen; Celgene
Consulting or Advisory Role - Celgene
Speakers' Bureau - Amgen; Celgene
Research Funding - Seattle Genetics/Astellas
 
Hun Ju Lee
Consulting or Advisory Role - Bristol-Myers Squibb; Guidepoint Global
Research Funding - Bristol-Myers Squibb; Celgene; Celgene; Oncternal Therapeutics; Seagen; Takeda
 
Linda Ho
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Research Funding - Seagen
Travel, Accommodations, Expenses - Seagen
 
Ian Flinn
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Gilead Sciences (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Nurix (Inst); Roche (Inst); Seagen (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)